Corrigendum to “Modulation of dendritic spines and synaptic function by Rac1: A possible link to fragile X syndrome pathology” [Brain Res. 1399 (2011) 79–95]

2011 ◽  
Vol 1423 ◽  
pp. 114-115
Author(s):  
Odelia Y.N. Bongmba ◽  
Luis A. Martinez ◽  
Mary E. Elhardt ◽  
Karlis Butler ◽  
Maria V. Tejada-Simon
Keyword(s):  
Fragile X Syndrome ◽  
Dendritic Spines ◽  
Fragile X ◽  
Synaptic Function

scholarly journals Aberrant Rac1-cofilin signaling mediates defects in dendritic spines, synaptic function, and sensory perception in fragile X syndrome

2017 ◽  
Vol 10 (504) ◽  
pp. eaan0852 ◽  
Author(s):  
Alexander Pyronneau ◽  
Qionger He ◽  
Jee-Yeon Hwang ◽  
Morgan Porch ◽  
Anis Contractor ◽  
...  
Keyword(s):  
Fragile X Syndrome ◽  
Dendritic Spines ◽  
Fragile X ◽  
Sensory Perception ◽  
Synaptic Function

scholarly journals Modulation of dendritic spines and synaptic function by Rac1: A possible link to Fragile X syndrome pathology

2011 ◽  
Vol 1399 ◽  
pp. 79-95 ◽  
Author(s):  
Odelia Y.N. Bongmba ◽  
Luis A. Martinez ◽  
Mary E. Elhardt ◽  
Karlis Butler ◽  
Maria V. Tejada-Simon
Keyword(s):  
Fragile X Syndrome ◽  
Dendritic Spines ◽  
Fragile X ◽  
Synaptic Function

scholarly journals Abnormal intrinsic dynamics of dendritic spines in a fragile X syndrome mouse model in vivo

2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Akira Nagaoka ◽  
Hiroaki Takehara ◽  
Akiko Hayashi-Takagi ◽  
Jun Noguchi ◽  
Kazuhiko Ishii ◽  
...  
Keyword(s):  
Mouse Model ◽  
Fragile X Syndrome ◽  
Dendritic Spines ◽  
Fragile X

scholarly journals FMRP(1–297)-tat restores ion channel and synaptic function in a model of Fragile X syndrome

2020 ◽  
Vol 11 (1) ◽  
Author(s):  
Xiaoqin Zhan ◽  
Hadhimulya Asmara ◽  
Ning Cheng ◽  
Giriraj Sahu ◽  
Eduardo Sanchez ◽  
...  
Keyword(s):  
Ion Channel ◽  
Fragile X Syndrome ◽  
Fragile X ◽  
Synaptic Function

scholarly journals Interference of the complex between NCS-1 and Ric8a with phenothiazines regulates synaptic function and is an approach for fragile X syndrome

2017 ◽  
Vol 114 (6) ◽  
pp. E999-E1008 ◽  
Author(s):  
Alicia Mansilla ◽  
Antonio Chaves-Sanjuan ◽  
Nuria E. Campillo ◽  
Ourania Semelidou ◽  
Loreto Martínez-González ◽  
...  
Keyword(s):  
Fragile X Syndrome ◽  
Genetic Manipulation ◽  
Fragile X ◽  
Synaptic Function ◽  
Chemical Library ◽  
Mechanism Of Inhibition ◽  
Guanine Exchange Factor ◽  
Potential Inhibitors ◽  
Synaptic Effects ◽  
Potential Use

The protein complex formed by the Ca2+ sensor neuronal calcium sensor 1 (NCS-1) and the guanine exchange factor protein Ric8a coregulates synapse number and probability of neurotransmitter release, emerging as a potential therapeutic target for diseases affecting synapses, such as fragile X syndrome (FXS), the most common heritable autism disorder. Using crystallographic data and the virtual screening of a chemical library, we identified a set of heterocyclic small molecules as potential inhibitors of the NCS-1/Ric8a interaction. The aminophenothiazine FD44 interferes with NCS-1/Ric8a binding, and it restores normal synapse number and associative learning in a Drosophila FXS model. The synaptic effects elicited by FD44 feeding are consistent with the genetic manipulation of NCS-1. The crystal structure of NCS-1 bound to FD44 and the structure–function studies performed with structurally close analogs explain the FD44 specificity and the mechanism of inhibition, in which the small molecule stabilizes a mobile C-terminal helix inside a hydrophobic crevice of NCS-1 to impede Ric8a interaction. Our study shows the drugability of the NCS-1/Ric8a interface and uncovers a suitable region in NCS-1 for development of additional drugs of potential use on FXS and related synaptic disorders.

Fragile X Syndrome in Humans and Mice

1996 ◽  
Vol 45 (1-2) ◽  
pp. 93-108 ◽  
Author(s):  
B. A. Oostra
Keyword(s):  
Mental Retardation ◽  
Fragile X Syndrome ◽  
Dendritic Spines ◽  
Pyramidal Neurons ◽  
Fragile Site ◽  
Fragile X ◽  
Methylation Status ◽  
Physical Symptoms ◽  
Post Mortem Brain ◽  
Iq Scores

Fragile X syndrome is the most common cause of interited mental retardation in humans, with a frequency of approximately 1 in 1200 males and 1 in 2500 females [1]. It is second only to Down syndrome as a genetic cause of mental retardation, which has an overall frequency of 1 in 600. These frequency estimates suggest that fragile X syndrome accounts for approximately 3% of mental retardation in males, and perhaps as much as 20% in males with IQs between 30 and 55 [2]. The disease derives its name from the observation of a fragile site at Xq27.3 in cultured lymphocytes, fibroblasts and amniocytes [3].The phenotype of the fragile X syndrome is mental retardation, usually with an IQ in the 4-70 range [4] and a number of dysmorphic features: long face, everted ears and large testicles [for review see ref. 5] (Fig. 1). Not every patient shows all the physical symptoms, which are generally more apparent after childhood. Macroorchidism is a common feature of fragile X syndrome in more than 90% of postpuberal males. Some patients show hyperactivity and attention deficits as well as avoidance behaviour similar to autism. Affected females generally have a less severe clinical presentation, and their IQ scores are generally higher, with typically borderline IQs or mild mental retardation.No gross pathological abnormalities have been described in the brains of fragile X patients. Only a few post-mortem brain studies of fragile X males have been described and the information is very limited, presenting only non-specific findings such as brain atrophy, ventricular dilatation and pyramidal neurons with abnormal dendritic spines. It has been shown that the volume of the hippocampus was enlarged compared to controls [6], while a significantly decreased size of the posterior cerebellar vermis and increased size of the fourth ventricle was found [7]. Using magnetic resonance imaging it was shown that fragile X patients have an increased volume of the caudate nucleus [8]. The caudate volume is correlated with IQ and methylation status of the FMR1 gene.

scholarly journals Effects of the sigma-1 receptor agonist blarcamesine in a murine model of fragile X syndrome: neurobehavioral phenotypes and receptor occupancy

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Samantha T. Reyes ◽  
Robert M. J. Deacon ◽  
Scarlett G. Guo ◽  
Francisco J. Altimiras ◽  
Jessa B. Castillo ◽  
...  
Keyword(s):  
Fragile X Syndrome ◽  
Neurodevelopmental Disorders ◽  
Fragile X ◽  
Regional Distribution ◽  
Receptor Occupancy ◽  
Autism Spectrum ◽  
Contextual Fear Conditioning ◽  
Synaptic Function ◽  
Sigma 1 Receptor ◽  
Sigma 1

AbstractFragile X syndrome (FXS), a disorder of synaptic development and function, is the most prevalent genetic form of intellectual disability and autism spectrum disorder. FXS mouse models display clinically-relevant phenotypes, such as increased anxiety and hyperactivity. Despite their availability, so far advances in drug development have not yielded new treatments. Therefore, testing novel drugs that can ameliorate FXS’ cognitive and behavioral impairments is imperative. ANAVEX2-73 (blarcamesine) is a sigma-1 receptor (S1R) agonist with a strong safety record and preliminary efficacy evidence in patients with Alzheimer’s disease and Rett syndrome, other synaptic neurodegenerative and neurodevelopmental disorders. S1R’s role in calcium homeostasis and mitochondrial function, cellular functions related to synaptic function, makes blarcamesine a potential drug candidate for FXS. Administration of blarcamesine in 2-month-old FXS and wild type mice for 2 weeks led to normalization in two key neurobehavioral phenotypes: open field test (hyperactivity) and contextual fear conditioning (associative learning). Furthermore, there was improvement in marble-burying (anxiety, perseverative behavior). It also restored levels of BDNF, a converging point of many synaptic regulators, in the hippocampus. Positron emission tomography (PET) and ex vivo autoradiographic studies, using the highly selective S1R PET ligand [18F]FTC-146, demonstrated the drug’s dose-dependent receptor occupancy. Subsequent analyses also showed a wide but variable brain regional distribution of S1Rs, which was preserved in FXS mice. Altogether, these neurobehavioral, biochemical, and imaging data demonstrates doses that yield measurable receptor occupancy are effective for improving the synaptic and behavioral phenotype in FXS mice. The present findings support the viability of S1R as a therapeutic target in FXS, and the clinical potential of blarcamesine in FXS and other neurodevelopmental disorders.

scholarly journals Hyperexcitability and Homeostasis in Fragile X Syndrome

2022 ◽  
Vol 14 ◽  
Author(s):  
Xiaopeng Liu ◽  
Vipendra Kumar ◽  
Nien-Pei Tsai ◽  
Benjamin D. Auerbach
Keyword(s):  
Fragile X Syndrome ◽  
Fragile X ◽  
Inhibitory Neuron ◽  
Cell Types ◽  
Developmental Time ◽  
Brain Regions ◽  
Synaptic Function ◽  
Homeostatic Plasticity ◽  
Neuron Activity ◽  
The Impact

Fragile X Syndrome (FXS) is a leading inherited cause of autism and intellectual disability, resulting from a mutation in the FMR1 gene and subsequent loss of its protein product FMRP. Despite this simple genetic origin, FXS is a phenotypically complex disorder with a range of physical and neurocognitive disruptions. While numerous molecular and cellular pathways are affected by FMRP loss, there is growing evidence that circuit hyperexcitability may be a common convergence point that can account for many of the wide-ranging phenotypes seen in FXS. The mechanisms for hyperexcitability in FXS include alterations to excitatory synaptic function and connectivity, reduced inhibitory neuron activity, as well as changes to ion channel expression and conductance. However, understanding the impact of FMR1 mutation on circuit function is complicated by the inherent plasticity in neural circuits, which display an array of homeostatic mechanisms to maintain activity near set levels. FMRP is also an important regulator of activity-dependent plasticity in the brain, meaning that dysregulated plasticity can be both a cause and consequence of hyperexcitable networks in FXS. This makes it difficult to separate the direct effects of FMR1 mutation from the myriad and pleiotropic compensatory changes associated with it, both of which are likely to contribute to FXS pathophysiology. Here we will: (1) review evidence for hyperexcitability and homeostatic plasticity phenotypes in FXS models, focusing on similarities/differences across brain regions, cell-types, and developmental time points; (2) examine how excitability and plasticity disruptions interact with each other to ultimately contribute to circuit dysfunction in FXS; and (3) discuss how these synaptic and circuit deficits contribute to disease-relevant behavioral phenotypes like epilepsy and sensory hypersensitivity. Through this discussion of where the current field stands, we aim to introduce perspectives moving forward in FXS research.

scholarly journals An aminophenothiazine inhibitor of the NCS-1/Ric8a complex regulates synaptic function in fragile X syndrome

2018 ◽  
Vol 74 (a2) ◽  
pp. e38-e39
Author(s):  
Maria Jose Sanchez-Barrena ◽  
Alicia Mansilla ◽  
Antonio Chaves-Sanjuán ◽  
Nuria Campillo ◽  
Ourania Semelidou ◽  
...  
Keyword(s):  
Fragile X Syndrome ◽  
Fragile X ◽  
Synaptic Function
Sign in / Sign up

Export Citation Format

Share Document